This Montelukast has an average rating of 5
Accolate (zafirlukast) Singulair (montelukast) Prescription only Prescribed for Asthma - Maintenance
Zafirlukast Versus Montelukast
Abstract Introduction: Asthma is one of the most common respiratory disorders in clinical practice, afecting up to 13% of people worldwide
Results: The cromolyn sodium, montelukast, and zafirlukast groups had less acute inflammation as well as lower mean inflammation severity scores, foreign body reaction
montelukast) or in the related class of 5-lipoxygenase inhibitors PDF | On Jan 1, 2019, Burcu Volkan published A Comparison of the Effectiveness of Montelukast and Zafirlukast Theraphy in Children with Asthma | Find, read and cite all the research you need on Direct comparison with inhaled corticosteroids shows that both zafirlukast and montelukast are no more potent than beclomethasone dipropionate 400 microgram daily
Patients were consecutively divided into 2 groups, and the first group was given 5 mg of montelukast before sleep and the second group These parameters were better in the cromolyn sodium group than in the montelukast and zafirlukast groups ( p < 0
4 out of 10 from a total of 553 ratings on Drugs
Ratings & Reviews: Accolate has an average rating of 10
8, 9 In recent years, montelukast has been reported to have beneficial pharmacological effects in the nervous, 10 cardiovascular, 8 and cerebrovascular systems
Leukotrienes are eicosanoid inflammatory mediators derived from arachidonic acid
45% of reviewers reported a positive effect, while 35% reported a negative
" by W
Accolate (zafirlukast) and Singulair (montelukast) are leukotriene receptor antagonists
Zafirlukast is available in 10 and 20 mg tablets generically and under the brand name Accolate
As per the Global Initiative for Asthma (GINA) guidelines, LTRA, including montelukast or zafirlukast, is an essential controller therapy for patients who cannot tolerate inhaled corticosteroids
Montelukast has been shown to reduce symptoms of asthma and allergic rhinitis and prevent acute attacks
A comparison of adverse events reported by ≥1% of zafirlukast-treated patients, and at rates numerically greater than in placebo-treated patients, is shown for all trials in the table below